Sutro Biopharma, Inc.’s Post

New Drugs on the Horizon sessions feature first disclosures of 12 new anticancer therapies This year's three New Drugs on the Horizon sessions featured first disclosures on the structure, mechanism of action, and functional target modulation of 12 novel cancer agents

Targeting Cancer with Fewer Side Effects 🧬💊 Overexpression of the BCL-XL protein, linked to drug resistance in many cancers, has been a key therapeutic target. While small-molecule inhibitors showed promise, they caused severe cardiovascular toxicity. Researchers have developed antibody-drug conjugates (ADCs) to overcome these challenges. The ADC AM1-25 has shown effectiveness in preclinical models without the dangerous side effects. It represents a breakthrough in cancer treatment and is now being tested in human clinical trials under the name mirzotamab clezutoclax. #CancerResearch #BCLXL #AntibodyTherapy #ClinicalTrials

In a Nature News Article earlier this year, it's clear that the radiopharma market is on the up, driven by the success of next-generation radiopharmaceuticals like Pluvicto and Lutathera. These innovative therapies, which deliver targeted radiation to cancer cells, are reshaping oncology by improving outcomes with fewer side effects. The potential for combining diagnostics and treatments in "theranostics" is particularly exciting, offering personalized, precise treatments. Pharma giants like Novartis and Eli Lilly are making billion-dollar acquisitions, signalling confidence in this field's future. With increased venture capital and dealmaking, radiopharmaceuticals are set to play a transformative role in cancer care.

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Gilead forms pact with Cartography to map new targets for cancer drugs: Gilead will work with fellow California biotech Cartography Biosciences to find new targets for breast and lung cancer medicines, the companies said Tuesday morning. The deal includes $20 million upfront and an undisclosed amount in milestone payments, plus potential tiered royalties, the pair said. The deal focuses on triple-negative breast cancer and adenocarcinoma, the most prevalent type of non-small cell lung cancer. It marks the first pharma partnership for Cartography, which emerged with $57 million in the summer of 2022. The nimble startup will use its so-called ATLAS and SUMMIT platforms to find single and paired targets that Gilead can elect to drug against with its own therapies. ATLAS finds single targets, while the newer SUMMIT platform helps to “dramatically expand the search space” by combing through two-antigen target combinations, founder and CEO Kevin Parker told Endpoints News. “We need new mechanisms to target tumors. We need new ways to reach patients. It feels like the elephant in the room for the biopharma space in that we’re iterating and engineering better and better drug modalities, but running out of targets to develop them against,” Parker said in an interview. “If you don’t have those good targets, you’re leaving patients behind.” Gilead will decide which modalities it uses to drug the targets, Parker said. In oncology, the drugmaker markets cell therapies by way of its Kite Pharma unit, as well as the antibody-drug conjugate Trodelvy and the PI3 kinase inhibitor Zydelig, which has run into confirmatory trial hurdles in the past. Cartography’s internal pipeline is led by a T cell engager for colorectal cancer, called CB21. The 45-employee startup will have more information on the timing of its CB21 clinical development plans later this year, Parker said. Colorectal cancer is the “second leading cause of death in oncology in the US,” he added. Gilead has been active on the external hunt for new oncology medicines as it seeks to have 20 or more indication approvals in cancer by the end of this decade. It has recently lined up partnerships with Xilio Therapeutics, Merus and others. Meanwhile, it’s pulled back on its CD47 work in oncology, casting further shadows on its $4.9 billion Forty Seven acquisition. #lucidquest #genetherapy #celltherapy

Hemi portfolio Mythic Therapeutics, Inc. announced the publication of preclinical data on MYTX-011, their investigational cMET-targeting antibody-drug conjugate (ADC), in Molecular Cancer Therapeutics. The study highlights MYTX-011's pH-dependent binding, which improves payload delivery to tumors with medium to low cMET expression, potentially benefiting a broader range of patients. Preclinical results show that MYTX-011 achieves higher internalization and cytotoxicity than non-pH engineered ADCs, demonstrating superior efficacy in various cancer models. Currently, MYTX-011 is undergoing Phase 1 clinical trials to further evaluate its safety and effectiveness. #HemiBio Brian Fiske  https://lnkd.in/e8YpprJd

Life Science Leader has recognized Promontory Therapeutics as a Company to Watch for our innovative approach to developing immunogenic small molecules. Unlike most immunotherapies that rely on antibodies or cell therapy, our small molecule agent, PT-112, can inhibit tumor growth by starving cancer cells of ribosomes, subsequently leading to activation of the anticancer-immune response. Promontory CEO Robert Fallon describes this unique approach in the profile below. PT-112 is currently in Phase 2 trials for prostate cancer and in rare cancers of the thymus, and Promontory has also reported early Phase 2 combination data in lung cancers. #biotech #biopharma #cancerresearch #smallmoleculeI_O #immunooncology #immunotherapy #oncology Read more about Promontory and the “Return of Small Molecules”:

"Drug the undruggable" It's time for PROTACs - protein degraders to change the treatment landscape. Novartis partners with Arvinas for the global license of ARV-766 (Currently in Ph 1/2), a PROTAC AR protein degrader as a potential first-in-class treatment option for patients with prostate cancer. > Arvinas will receive a $150 Mn upfront payment for the license of ARV-766 and the sale of the preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 Bn in development, regulatory, and commercial milestones as well as tiered royalties. > Novartis to be responsible for worldwide clinical development and commercialization of ARV-766. #Novartis #Arvinas #ARV766 #PROTACs #Protiendegraders

New Drug Candidates In Cancer : Disclosure at American Association for Cancer Research, 2024 The discovery and development of New drug candidates spanning across best in class or new class belonging to different modalities PROTACS, ADCs, Small molecules, and Theranostics are being presented in this exciting session at AACR. Presenters present their experience in different stages of drug discovery and development in cancer. These are first disclosures of structures of molecules and their targets. A great opportunity to learn Drug Discovery and development in cancer.

📢 Exciting News! Our latest blog post dives into the future of Antibody-Drug Conjugates (ADCs), one of the most promising advancements in targeted cancer therapy. ADCs combine the precision of monoclonal antibodies with the potency of chemotherapy, delivering drugs directly to cancer cells while minimizing damage to healthy tissue. The global market for ADCs is projected to skyrocket from $10.8 billion in 2023 to an impressive $47.0 billion by 2029, growing at a CAGR of 28.4%. The increasing need for effective cancer treatments and advanced ADC technologies drives this surge. Want to know more about how ADCs are revolutionizing oncology and what the future holds for this booming market? Check out our full analysis for key trends, growth drivers, and forecasts over the next five years. 🌱 https://bit.ly/3YjlxIk #AntibodyDrugConjugates #ADCTherapy #CancerTreatment #Biopharma #PharmaTrends #HealthcareInnovation #GlobalMarkets

Our new preprint titled “Anticancer Target Combinations: Network-Informed Signaling-Based Approach to Discovery” is now available on bioRxiv: https://lnkd.in/e3ZrnANN Our approach aims to overcome the limitations of single-drug therapies by strategically blocking parallel or complementary signaling pathways, leveraging tumor mutations and PPI networks. This tool could transform how oncologists select proteins for drug combinations, shifting from empirical observations to network-informed, data-driven decisions for personalized cancer treatment. Highlights: - Concept-based stratified pipeline for co-target selection - Focus on signaling pathways to combat drug resistance - Utilization of network concepts and tissue-specific co-existing mutations - Strategy to shut off cancer's alternative proliferation routes #CancerResearch #CombinationTherapy #PrecisionMedicine #DrugDiscovery #SystemsBiology